Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report

BACKGROUND: The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage that excludes them from potentially curative surgical treatment. Lenvatinib is associated with a high objective response rate (ORR) (40.6%) in advanced HCC, indicating the potential for tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhaobo, Fu, Zhi, Li, Guangming, Lin, Dongdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568629/
https://www.ncbi.nlm.nih.gov/pubmed/33116607
http://dx.doi.org/10.2147/OTT.S261521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568629/
https://www.ncbi.nlm.nih.gov/pubmed/33116607
http://dx.doi.org/10.2147/OTT.S261521

Ejemplares similares